Mechanism To Assess Trade Agreements Needed, UN Forum On Access To Medicines Hears 10/10/2017 Peter Kenny Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 A mechanism to systematically assess trade agreements from a public health perspective, including accession agreements of the World Trade Organization and European Patent Office’s validation agreements is needed, says Ellen ´t Hoen, senior researcher at the Global Health Unit of the University Medical Centre, Groningen, The Netherlands, who publishes the Medicines Law and Policy website. Continue reading -> Canadian Universities Not Contributing Enough To Neglected Health Needs, UAEM Report Says 03/10/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 The Universities Allied for Essential medicines (UAEM) evaluated 15 Canadian research-intensive universities on their contributions to biomedical research on neglected health needs, access to medicines, and education concerning access and innovation issues. The results show that for a number of those universities, this contribution is sub-optimal. Continue reading -> 2017 Social Forum Focuses On HIV, Other Epidemics, Access To Health 29/09/2017 Catherine Saez The 2017 Social Forum, an annual meeting convened by the Human Rights Council, is being held next week in Geneva, and will focus on the promotion and protection of human rights in the context of the HIV epidemic and other communicable diseases and epidemics. Continue reading -> Use Competition Law For Wider Access To Cheap Medicines? 27/09/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 The topic of access to medicines has gained momentum in recent years as high prices of new medicines affect developing countries and developed countries. The role of competition legislation in preventing market abuses and monopoly situations has been pointed to as a possible lever to facilitate access to generic medicines and balance the potential negative effects of intellectual property protection. Continue reading -> WHO Issues Alarming Report On Coming Shortage Of Antibiotics 20/09/2017 William New A new report issued today by the World Health Organization shows a “serious lack” of new antibiotics in development, even as resistance to existing antibiotics are on the rise. The head of the WHO said the report shows an “urgent need” for investment into research and development. In addition, a second report today from WHO on prioritisation of pathogens for R&D into new antibiotics. Continue reading -> Access To Generic Reproductive Health Supplies Decades Behind Medicines? 19/09/2017 Tatum Anderson Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 Despite a massive worldwide push to improve access to contraceptives, generic manufacturers say they’re not yet getting a good share of the pie. Continue reading -> Malaysia Grants Compulsory Licence For Generic Sofosbuvir Despite Gilead Licence 15/09/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 A much cheaper version of a groundbreaking hepatitis C medicine is expected to be available soon for the hundreds of thousands of hepatitis C patients in Malaysia, as it decided to grant a compulsory licence to sofosbuvir, according to sources. The decision comes right after the medicine originator decided to expand its voluntary licensing scheme to four more countries, including Malaysia. Continue reading -> Workshop To Address Public Interest And CRISPR Gene Editing, CAR T Cancer Treatment 04/09/2017 William New Experts at a one-day workshop in Washington DC on 15 September will discuss public interest aspects of patents and two breakthrough new medical technologies related to gene editing (CRISPR) and cancer treatment (CAR T). Continue reading -> Better Data On Fake Drugs Needed To Fight The Scourge 30/08/2017 Tatum Anderson Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 The problem of fake medicines is a big one. But precisely how big? Continue reading -> Malaysia Inclusion In Gilead Voluntary Licence – A Product Of Compulsory Licence Pressure 24/08/2017 Guest contributor Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 By Fifa Rahman Gilead’s announcement today that they would include four middle-income countries (Malaysia, Thailand, Belarus, Ukraine) in their sofosbuvir voluntary licence was a welcome surprise, and will enable millions access to their highly effective, but exorbitantly priced, drug. The decision to include these countries, however, no doubt is a response to increasing pressure from within these countries to either issue a compulsory licence (CL) or a government use licence (GUL), invalidate the sofosbuvir patents, or block data exclusivity for the drug. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Canadian Universities Not Contributing Enough To Neglected Health Needs, UAEM Report Says 03/10/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 The Universities Allied for Essential medicines (UAEM) evaluated 15 Canadian research-intensive universities on their contributions to biomedical research on neglected health needs, access to medicines, and education concerning access and innovation issues. The results show that for a number of those universities, this contribution is sub-optimal. Continue reading -> 2017 Social Forum Focuses On HIV, Other Epidemics, Access To Health 29/09/2017 Catherine Saez The 2017 Social Forum, an annual meeting convened by the Human Rights Council, is being held next week in Geneva, and will focus on the promotion and protection of human rights in the context of the HIV epidemic and other communicable diseases and epidemics. Continue reading -> Use Competition Law For Wider Access To Cheap Medicines? 27/09/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 The topic of access to medicines has gained momentum in recent years as high prices of new medicines affect developing countries and developed countries. The role of competition legislation in preventing market abuses and monopoly situations has been pointed to as a possible lever to facilitate access to generic medicines and balance the potential negative effects of intellectual property protection. Continue reading -> WHO Issues Alarming Report On Coming Shortage Of Antibiotics 20/09/2017 William New A new report issued today by the World Health Organization shows a “serious lack” of new antibiotics in development, even as resistance to existing antibiotics are on the rise. The head of the WHO said the report shows an “urgent need” for investment into research and development. In addition, a second report today from WHO on prioritisation of pathogens for R&D into new antibiotics. Continue reading -> Access To Generic Reproductive Health Supplies Decades Behind Medicines? 19/09/2017 Tatum Anderson Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 Despite a massive worldwide push to improve access to contraceptives, generic manufacturers say they’re not yet getting a good share of the pie. Continue reading -> Malaysia Grants Compulsory Licence For Generic Sofosbuvir Despite Gilead Licence 15/09/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 A much cheaper version of a groundbreaking hepatitis C medicine is expected to be available soon for the hundreds of thousands of hepatitis C patients in Malaysia, as it decided to grant a compulsory licence to sofosbuvir, according to sources. The decision comes right after the medicine originator decided to expand its voluntary licensing scheme to four more countries, including Malaysia. Continue reading -> Workshop To Address Public Interest And CRISPR Gene Editing, CAR T Cancer Treatment 04/09/2017 William New Experts at a one-day workshop in Washington DC on 15 September will discuss public interest aspects of patents and two breakthrough new medical technologies related to gene editing (CRISPR) and cancer treatment (CAR T). Continue reading -> Better Data On Fake Drugs Needed To Fight The Scourge 30/08/2017 Tatum Anderson Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 The problem of fake medicines is a big one. But precisely how big? Continue reading -> Malaysia Inclusion In Gilead Voluntary Licence – A Product Of Compulsory Licence Pressure 24/08/2017 Guest contributor Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 By Fifa Rahman Gilead’s announcement today that they would include four middle-income countries (Malaysia, Thailand, Belarus, Ukraine) in their sofosbuvir voluntary licence was a welcome surprise, and will enable millions access to their highly effective, but exorbitantly priced, drug. The decision to include these countries, however, no doubt is a response to increasing pressure from within these countries to either issue a compulsory licence (CL) or a government use licence (GUL), invalidate the sofosbuvir patents, or block data exclusivity for the drug. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
2017 Social Forum Focuses On HIV, Other Epidemics, Access To Health 29/09/2017 Catherine Saez The 2017 Social Forum, an annual meeting convened by the Human Rights Council, is being held next week in Geneva, and will focus on the promotion and protection of human rights in the context of the HIV epidemic and other communicable diseases and epidemics. Continue reading -> Use Competition Law For Wider Access To Cheap Medicines? 27/09/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 The topic of access to medicines has gained momentum in recent years as high prices of new medicines affect developing countries and developed countries. The role of competition legislation in preventing market abuses and monopoly situations has been pointed to as a possible lever to facilitate access to generic medicines and balance the potential negative effects of intellectual property protection. Continue reading -> WHO Issues Alarming Report On Coming Shortage Of Antibiotics 20/09/2017 William New A new report issued today by the World Health Organization shows a “serious lack” of new antibiotics in development, even as resistance to existing antibiotics are on the rise. The head of the WHO said the report shows an “urgent need” for investment into research and development. In addition, a second report today from WHO on prioritisation of pathogens for R&D into new antibiotics. Continue reading -> Access To Generic Reproductive Health Supplies Decades Behind Medicines? 19/09/2017 Tatum Anderson Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 Despite a massive worldwide push to improve access to contraceptives, generic manufacturers say they’re not yet getting a good share of the pie. Continue reading -> Malaysia Grants Compulsory Licence For Generic Sofosbuvir Despite Gilead Licence 15/09/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 A much cheaper version of a groundbreaking hepatitis C medicine is expected to be available soon for the hundreds of thousands of hepatitis C patients in Malaysia, as it decided to grant a compulsory licence to sofosbuvir, according to sources. The decision comes right after the medicine originator decided to expand its voluntary licensing scheme to four more countries, including Malaysia. Continue reading -> Workshop To Address Public Interest And CRISPR Gene Editing, CAR T Cancer Treatment 04/09/2017 William New Experts at a one-day workshop in Washington DC on 15 September will discuss public interest aspects of patents and two breakthrough new medical technologies related to gene editing (CRISPR) and cancer treatment (CAR T). Continue reading -> Better Data On Fake Drugs Needed To Fight The Scourge 30/08/2017 Tatum Anderson Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 The problem of fake medicines is a big one. But precisely how big? Continue reading -> Malaysia Inclusion In Gilead Voluntary Licence – A Product Of Compulsory Licence Pressure 24/08/2017 Guest contributor Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 By Fifa Rahman Gilead’s announcement today that they would include four middle-income countries (Malaysia, Thailand, Belarus, Ukraine) in their sofosbuvir voluntary licence was a welcome surprise, and will enable millions access to their highly effective, but exorbitantly priced, drug. The decision to include these countries, however, no doubt is a response to increasing pressure from within these countries to either issue a compulsory licence (CL) or a government use licence (GUL), invalidate the sofosbuvir patents, or block data exclusivity for the drug. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Use Competition Law For Wider Access To Cheap Medicines? 27/09/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 The topic of access to medicines has gained momentum in recent years as high prices of new medicines affect developing countries and developed countries. The role of competition legislation in preventing market abuses and monopoly situations has been pointed to as a possible lever to facilitate access to generic medicines and balance the potential negative effects of intellectual property protection. Continue reading -> WHO Issues Alarming Report On Coming Shortage Of Antibiotics 20/09/2017 William New A new report issued today by the World Health Organization shows a “serious lack” of new antibiotics in development, even as resistance to existing antibiotics are on the rise. The head of the WHO said the report shows an “urgent need” for investment into research and development. In addition, a second report today from WHO on prioritisation of pathogens for R&D into new antibiotics. Continue reading -> Access To Generic Reproductive Health Supplies Decades Behind Medicines? 19/09/2017 Tatum Anderson Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 Despite a massive worldwide push to improve access to contraceptives, generic manufacturers say they’re not yet getting a good share of the pie. Continue reading -> Malaysia Grants Compulsory Licence For Generic Sofosbuvir Despite Gilead Licence 15/09/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 A much cheaper version of a groundbreaking hepatitis C medicine is expected to be available soon for the hundreds of thousands of hepatitis C patients in Malaysia, as it decided to grant a compulsory licence to sofosbuvir, according to sources. The decision comes right after the medicine originator decided to expand its voluntary licensing scheme to four more countries, including Malaysia. Continue reading -> Workshop To Address Public Interest And CRISPR Gene Editing, CAR T Cancer Treatment 04/09/2017 William New Experts at a one-day workshop in Washington DC on 15 September will discuss public interest aspects of patents and two breakthrough new medical technologies related to gene editing (CRISPR) and cancer treatment (CAR T). Continue reading -> Better Data On Fake Drugs Needed To Fight The Scourge 30/08/2017 Tatum Anderson Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 The problem of fake medicines is a big one. But precisely how big? Continue reading -> Malaysia Inclusion In Gilead Voluntary Licence – A Product Of Compulsory Licence Pressure 24/08/2017 Guest contributor Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 By Fifa Rahman Gilead’s announcement today that they would include four middle-income countries (Malaysia, Thailand, Belarus, Ukraine) in their sofosbuvir voluntary licence was a welcome surprise, and will enable millions access to their highly effective, but exorbitantly priced, drug. The decision to include these countries, however, no doubt is a response to increasing pressure from within these countries to either issue a compulsory licence (CL) or a government use licence (GUL), invalidate the sofosbuvir patents, or block data exclusivity for the drug. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO Issues Alarming Report On Coming Shortage Of Antibiotics 20/09/2017 William New A new report issued today by the World Health Organization shows a “serious lack” of new antibiotics in development, even as resistance to existing antibiotics are on the rise. The head of the WHO said the report shows an “urgent need” for investment into research and development. In addition, a second report today from WHO on prioritisation of pathogens for R&D into new antibiotics. Continue reading -> Access To Generic Reproductive Health Supplies Decades Behind Medicines? 19/09/2017 Tatum Anderson Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 Despite a massive worldwide push to improve access to contraceptives, generic manufacturers say they’re not yet getting a good share of the pie. Continue reading -> Malaysia Grants Compulsory Licence For Generic Sofosbuvir Despite Gilead Licence 15/09/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 A much cheaper version of a groundbreaking hepatitis C medicine is expected to be available soon for the hundreds of thousands of hepatitis C patients in Malaysia, as it decided to grant a compulsory licence to sofosbuvir, according to sources. The decision comes right after the medicine originator decided to expand its voluntary licensing scheme to four more countries, including Malaysia. Continue reading -> Workshop To Address Public Interest And CRISPR Gene Editing, CAR T Cancer Treatment 04/09/2017 William New Experts at a one-day workshop in Washington DC on 15 September will discuss public interest aspects of patents and two breakthrough new medical technologies related to gene editing (CRISPR) and cancer treatment (CAR T). Continue reading -> Better Data On Fake Drugs Needed To Fight The Scourge 30/08/2017 Tatum Anderson Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 The problem of fake medicines is a big one. But precisely how big? Continue reading -> Malaysia Inclusion In Gilead Voluntary Licence – A Product Of Compulsory Licence Pressure 24/08/2017 Guest contributor Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 By Fifa Rahman Gilead’s announcement today that they would include four middle-income countries (Malaysia, Thailand, Belarus, Ukraine) in their sofosbuvir voluntary licence was a welcome surprise, and will enable millions access to their highly effective, but exorbitantly priced, drug. The decision to include these countries, however, no doubt is a response to increasing pressure from within these countries to either issue a compulsory licence (CL) or a government use licence (GUL), invalidate the sofosbuvir patents, or block data exclusivity for the drug. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Access To Generic Reproductive Health Supplies Decades Behind Medicines? 19/09/2017 Tatum Anderson Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 Despite a massive worldwide push to improve access to contraceptives, generic manufacturers say they’re not yet getting a good share of the pie. Continue reading -> Malaysia Grants Compulsory Licence For Generic Sofosbuvir Despite Gilead Licence 15/09/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 A much cheaper version of a groundbreaking hepatitis C medicine is expected to be available soon for the hundreds of thousands of hepatitis C patients in Malaysia, as it decided to grant a compulsory licence to sofosbuvir, according to sources. The decision comes right after the medicine originator decided to expand its voluntary licensing scheme to four more countries, including Malaysia. Continue reading -> Workshop To Address Public Interest And CRISPR Gene Editing, CAR T Cancer Treatment 04/09/2017 William New Experts at a one-day workshop in Washington DC on 15 September will discuss public interest aspects of patents and two breakthrough new medical technologies related to gene editing (CRISPR) and cancer treatment (CAR T). Continue reading -> Better Data On Fake Drugs Needed To Fight The Scourge 30/08/2017 Tatum Anderson Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 The problem of fake medicines is a big one. But precisely how big? Continue reading -> Malaysia Inclusion In Gilead Voluntary Licence – A Product Of Compulsory Licence Pressure 24/08/2017 Guest contributor Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 By Fifa Rahman Gilead’s announcement today that they would include four middle-income countries (Malaysia, Thailand, Belarus, Ukraine) in their sofosbuvir voluntary licence was a welcome surprise, and will enable millions access to their highly effective, but exorbitantly priced, drug. The decision to include these countries, however, no doubt is a response to increasing pressure from within these countries to either issue a compulsory licence (CL) or a government use licence (GUL), invalidate the sofosbuvir patents, or block data exclusivity for the drug. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Malaysia Grants Compulsory Licence For Generic Sofosbuvir Despite Gilead Licence 15/09/2017 Catherine Saez Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 A much cheaper version of a groundbreaking hepatitis C medicine is expected to be available soon for the hundreds of thousands of hepatitis C patients in Malaysia, as it decided to grant a compulsory licence to sofosbuvir, according to sources. The decision comes right after the medicine originator decided to expand its voluntary licensing scheme to four more countries, including Malaysia. Continue reading -> Workshop To Address Public Interest And CRISPR Gene Editing, CAR T Cancer Treatment 04/09/2017 William New Experts at a one-day workshop in Washington DC on 15 September will discuss public interest aspects of patents and two breakthrough new medical technologies related to gene editing (CRISPR) and cancer treatment (CAR T). Continue reading -> Better Data On Fake Drugs Needed To Fight The Scourge 30/08/2017 Tatum Anderson Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 The problem of fake medicines is a big one. But precisely how big? Continue reading -> Malaysia Inclusion In Gilead Voluntary Licence – A Product Of Compulsory Licence Pressure 24/08/2017 Guest contributor Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 By Fifa Rahman Gilead’s announcement today that they would include four middle-income countries (Malaysia, Thailand, Belarus, Ukraine) in their sofosbuvir voluntary licence was a welcome surprise, and will enable millions access to their highly effective, but exorbitantly priced, drug. The decision to include these countries, however, no doubt is a response to increasing pressure from within these countries to either issue a compulsory licence (CL) or a government use licence (GUL), invalidate the sofosbuvir patents, or block data exclusivity for the drug. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Workshop To Address Public Interest And CRISPR Gene Editing, CAR T Cancer Treatment 04/09/2017 William New Experts at a one-day workshop in Washington DC on 15 September will discuss public interest aspects of patents and two breakthrough new medical technologies related to gene editing (CRISPR) and cancer treatment (CAR T). Continue reading -> Better Data On Fake Drugs Needed To Fight The Scourge 30/08/2017 Tatum Anderson Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 The problem of fake medicines is a big one. But precisely how big? Continue reading -> Malaysia Inclusion In Gilead Voluntary Licence – A Product Of Compulsory Licence Pressure 24/08/2017 Guest contributor Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 By Fifa Rahman Gilead’s announcement today that they would include four middle-income countries (Malaysia, Thailand, Belarus, Ukraine) in their sofosbuvir voluntary licence was a welcome surprise, and will enable millions access to their highly effective, but exorbitantly priced, drug. The decision to include these countries, however, no doubt is a response to increasing pressure from within these countries to either issue a compulsory licence (CL) or a government use licence (GUL), invalidate the sofosbuvir patents, or block data exclusivity for the drug. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Better Data On Fake Drugs Needed To Fight The Scourge 30/08/2017 Tatum Anderson Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 The problem of fake medicines is a big one. But precisely how big? Continue reading -> Malaysia Inclusion In Gilead Voluntary Licence – A Product Of Compulsory Licence Pressure 24/08/2017 Guest contributor Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 By Fifa Rahman Gilead’s announcement today that they would include four middle-income countries (Malaysia, Thailand, Belarus, Ukraine) in their sofosbuvir voluntary licence was a welcome surprise, and will enable millions access to their highly effective, but exorbitantly priced, drug. The decision to include these countries, however, no doubt is a response to increasing pressure from within these countries to either issue a compulsory licence (CL) or a government use licence (GUL), invalidate the sofosbuvir patents, or block data exclusivity for the drug. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Malaysia Inclusion In Gilead Voluntary Licence – A Product Of Compulsory Licence Pressure 24/08/2017 Guest contributor Warning: Attempt to read property "post_title" on null in /home/clients/58f2a29976672af522a8f4d82ffa28b6/web/wp-content/plugins/better-image-credits/better-image-credits.php on line 227 By Fifa Rahman Gilead’s announcement today that they would include four middle-income countries (Malaysia, Thailand, Belarus, Ukraine) in their sofosbuvir voluntary licence was a welcome surprise, and will enable millions access to their highly effective, but exorbitantly priced, drug. The decision to include these countries, however, no doubt is a response to increasing pressure from within these countries to either issue a compulsory licence (CL) or a government use licence (GUL), invalidate the sofosbuvir patents, or block data exclusivity for the drug. Continue reading -> Posts navigation Older postsNewer posts